NSAIDs for high-risk patients: none, celecoxib, or naproxen?
Volume
389
Pagination
2351 - 2352
Publisher
DOI
10.1016/S0140-6736(17)30981-9
Journal
LANCET
Issue
ISSN
0140-6736
Metadata
Show full item recordAbstract
Godot-like, the all-round safe and effective oral anti-inflammatory drug is awaited. Meantime, substantial effort is devoted to discovering how the existing imperfect non-steroidal anti-inflammatory drugs (NSAIDs) might be best used—balancing the need for effective analgesia with their multiple risks. The randomised controlled trial by Francis Chan and colleagues1 reported in The Lancet investigated two of these NSAIDs that have been seen as the best (or least worst) in the cardiovascular safety stakes, celecoxib and naproxen.
Authors
McGettigan, P; Olsen, A-MSURI
http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(17)30980-7.pdfhttp://qmro.qmul.ac.uk/xmlui/handle/123456789/36105